CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2616
-0.0030 (-1.13%)
Sep 29, 2025, 11:34 AM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
332.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | - | - | - |
| May 31, 2024 | - | - | - |
| May 31, 2023 | - | - | - |
| May 31, 2022 | 266.00K | - | - |
| May 31, 2021 | - | - | - |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| AMJ Global Technology | 39.00 |
CytoDyn News
- 4 days ago - CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 13 days ago - CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 25 days ago - CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 3 months ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 3 months ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 4 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga